SALATHÉ CAPITAL - Key Persons
Job Titles:
- Founding Investor & Founding Board Member
Dr. Richard Williams has managed, invested and consulted for more than 35 years in the start-up and development of 15 pre-public biotechnology companies. In this capacity he helped recruit management, focus business plans and raise initial capital while serving on the Boards of Directors. The most notable companies that into which Dr. Williams invested were Amgen, a major biotech firm, IGEN (acquired by Roche) and Supergen (acquired by Otsuka Pharma), all originally listed on NASDAQ stock exchange. For six years he was managing partner of Mara Venture Partners, LLC, an early-stage biotechnology venture capital fund with offices in Belgium and the US, and for 8 years served as an advisor to Vesalius Biocapital Fund, a private equity fund in the Benelux.
Mr. David Sturgeon has 15+ years of experience across various asset management roles and industries. Over the course of his career, Mr. Sturgeon has managed structured product investment portfolios for a family office and a hedge fund before developing the CSN.
Mr. Sturgeon is a graduate of the University of Northern Colorado, where he earned a BA in Management. He also earned a Masters of Science in Finance degree with an emphasis on fixed income from The Daniels College of Business at the University of Denver.